1. Home
  2. NG vs MYGN Comparison

NG vs MYGN Comparison

Compare NG & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NG
  • MYGN
  • Stock Information
  • Founded
  • NG 1984
  • MYGN 1991
  • Country
  • NG Canada
  • MYGN United States
  • Employees
  • NG N/A
  • MYGN N/A
  • Industry
  • NG Precious Metals
  • MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • NG Basic Materials
  • MYGN Health Care
  • Exchange
  • NG Nasdaq
  • MYGN Nasdaq
  • Market Cap
  • NG 1.1B
  • MYGN 1.2B
  • IPO Year
  • NG N/A
  • MYGN 1995
  • Fundamental
  • Price
  • NG $3.05
  • MYGN $14.18
  • Analyst Decision
  • NG
  • MYGN Hold
  • Analyst Count
  • NG 0
  • MYGN 13
  • Target Price
  • NG N/A
  • MYGN $22.54
  • AVG Volume (30 Days)
  • NG 2.2M
  • MYGN 1.2M
  • Earning Date
  • NG 04-02-2025
  • MYGN 02-24-2025
  • Dividend Yield
  • NG N/A
  • MYGN N/A
  • EPS Growth
  • NG N/A
  • MYGN N/A
  • EPS
  • NG N/A
  • MYGN N/A
  • Revenue
  • NG N/A
  • MYGN $823,600,000.00
  • Revenue This Year
  • NG N/A
  • MYGN $13.60
  • Revenue Next Year
  • NG N/A
  • MYGN $3.25
  • P/E Ratio
  • NG N/A
  • MYGN N/A
  • Revenue Growth
  • NG N/A
  • MYGN 12.15
  • 52 Week Low
  • NG $2.30
  • MYGN $12.04
  • 52 Week High
  • NG $4.88
  • MYGN $29.30
  • Technical
  • Relative Strength Index (RSI)
  • NG 42.06
  • MYGN 55.82
  • Support Level
  • NG $3.12
  • MYGN $14.13
  • Resistance Level
  • NG $3.28
  • MYGN $15.47
  • Average True Range (ATR)
  • NG 0.16
  • MYGN 0.72
  • MACD
  • NG -0.00
  • MYGN 0.27
  • Stochastic Oscillator
  • NG 8.97
  • MYGN 61.38

About NG Novagold Resources Inc.

Novagold Resources Inc is a mineral exploration company engaged in the exploration and development of mineral properties. The company owns 50% of the Donlin Gold project, which is located in southwestern Alaska, approximately 20 kilometers north of the village of Crooked Creek on the Kuskokwim River.

About MYGN Myriad Genetics Inc.

Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.

Share on Social Networks: